Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMDX with free AI briefings, catalyst countdowns, and dilution alerts.

IMDX · Insight Molecular Diagnostics I

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$11M Cash on Hand
4.2mo Cash Runway
Follow IMDX by email Get an email when IMDX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMDX, unsubscribe in one click. Privacy

📣 What IMDX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
adjuvanted trivalent influenza vaccine Influenza Phase 4 · NCT02882100 Completed
Baloxavir Influenza Phase 4 · NCT05012189 Unknown
Brimonidine Tartrate Ophthalmic 0.025% Glaucoma Phase 4 · NCT07209410 Recruiting
Oseltamivir Influenza Phase 4 · NCT05012189 Unknown
Trivalent Influenza Vaccine Influenza Phase 4 · NCT03965195 Unknown
Standard Dose Quadrivalent Influenza Vaccine Influenza Phase 4 · NCT03965195 Unknown
Influenza Influenza N/A · NCT03599739 Completed

Also used in these trials (approved or third-party drugs, not IMDX's own candidates): Adjuvant.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMDX holds $11M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.9M/quarter from operations, an estimated runway of 4.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 62 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMDX files for a raise →

👥 Who Owns IMDX

Insiders 50.3% Institutions (51 holders) 49.7% Public and other holders 0%
HolderTypeShares% of sharesAs of
Neal C. Bradsher Institution (13G, 5%+) 12,835,134 39.18% 2026-04-23
BROADWOOD PARTNERS, L.P.
10% owner · +150,093 options
Insider 12,685,041 38.72% 2026-04-23
Patrick W Smith
10% owner
Insider 3,258,485 9.95% 2025-02-07
Andrea S. James
Chief Financial Officer · +833,112 options
Insider 206,060 0.63% 2026-03-26
Andrew Arno
Director · +30,000 options
Insider 164,589 0.50% 2026-07-01
Andrew J. Last
Director · +30,000 options
Insider 58,752 0.18% 2026-07-01
Lou Silverman
Director · +30,000 options
Insider 55,807 0.17% 2026-07-01
Josh Riggs
CEO and President, Director · +730,188 options
Insider 38,365 0.12% 2026-03-26
James Yang Liu
VP ACCT, Cntlr, Treasurer, PAO · +59,445 options
Insider 3,711 0.01% 2026-03-26

Share count 32,757,434 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IMDX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMDX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.